PMID: 9538312Apr 16, 1998Paper

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost

Heart
T W HigenbottamS Akamine

Abstract

To compare prostacyclin with an analogue, iloprost, in treatment of severe pulmonary hypertension. Eight patients with severe pulmonary hypertension: primary in five, thromboembolic pulmonary hypertension in three. All patients underwent right heart catheterisation. Mean (SEM) right atrial pressure was 9.9 (2.2) mm Hg, mean pulmonary artery pressure 67.4 (3.0) mm Hg, cardiac index 1.75 (0.13) l/min/m2 and mixed venous oxygen saturation 59.1(3.1)%. Continuous intravenous epoprostenol (prostacyclin, PGI2) or iloprost was given for phase I (three to six weeks); the patients were then crossed over to receive the alternate drug in an equivalent phase II. Exercise tolerance was measured at baseline and at the end of phase I and II with a 12 minute walk; distance covered, rest period, percentage drop in arterial oxygen saturation (delta Sao2%) and percentage rise in heart rate (delta HR%). Walking distance covered rose from (mean (SEM)) 407.5 (73) to 591 (46) m with PGI2 (p = 0.004) and to 602.5 (60) m while on iloprost (p = 0.008). Rest period decreased from 192 (73) seconds at baseline to 16 (16) seconds with PGI2 (p = 0.01) and to 58 (34) seconds with iloprost (p = 0.008). Delta HR% was 37.5(6)% at baseline, 35(3)% on PGI2, and 24(...Continue Reading

Citations

Oct 19, 2013·Pharmacology & Therapeutics·David MontaniMarc Humbert
Jul 20, 2011·Nature Reviews. Cardiology·Dermot S O'CallaghanMarc Humbert
Apr 14, 1999·Comprehensive Therapy·H I Palevsky, I Gurughagavatula
Apr 17, 2010·Cardiology in Review·Joe R Anderson, James J Nawarskas
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Nazzareno GalièAngelo Branzi
Feb 8, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D SammutR Condliffe
Aug 20, 2009·Der Internist·R VoswinckelH A Ghofrani
May 9, 2009·Cardiology in the Young·Robyn J Barst, Duncan Stewart
May 7, 2002·American Journal of Respiratory and Critical Care Medicine·Marius M HoeperLewis J Rubin
Dec 1, 2008·Expert Review of Respiratory Medicine·Ralf EwertChristian Opitz
Aug 21, 2015·Expert Opinion on Pharmacotherapy·Swanny PerrinOlivier Sitbon
Feb 25, 2009·Expert Opinion on Drug Metabolism & Toxicology·Wouter Jacobs, Anton Vonk-Noordegraaf
Apr 27, 2001·Expert Opinion on Investigational Drugs·E Berman Rosenzweig, R J Barst
Nov 17, 2010·Expert Opinion on Drug Metabolism & Toxicology·Marie-Camille ChaumaisDavid Montani
Nov 26, 2015·Interactive Cardiovascular and Thoracic Surgery·Ismihan Selen OnanErsin Erek
Feb 2, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Zhi-Cheng JingYue-Jin Yang
Dec 17, 2008·Pulmonary Pharmacology & Therapeutics·Robert VoswinckelHorst Olschewski
Nov 24, 2007·La Presse médicale·Eric HachullaPierre-Yves Hatron
Sep 12, 2007·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Michael DandelRoland Hetzer
Mar 7, 2007·Clinics in Chest Medicine·Wayne L Strauss, Jeffrey D Edelman
May 28, 2004·Pharmacology & Therapeutics·Horst OlschewskiWerner Seeger
Sep 26, 2000·Italian Heart Journal : Official Journal of the Italian Federation of Cardiology·N Galiè
Mar 5, 2004·Journal of the American College of Cardiology·Hanno H LeuchteJürgen Behr
Jul 9, 2009·Journal of the American College of Cardiology·Robyn J BarstNazzareno Galiè
Jun 15, 2004·Journal of the American College of Cardiology·Nazzareno GalièLewis J Rubin
Feb 16, 2010·Respiratory Medicine·Horst OlschewskiWerner Seeger
Jul 24, 2007·Respiratory Medicine·Norbert WeissmannFriedrich Grimminger
Jun 25, 2005·The Annals of Pharmacotherapy·Stacey E Baker, Rebecca Haynes Hockman
Apr 13, 2017·Expert Review of Respiratory Medicine·R Del PozoP Escribano-Subias
Mar 15, 2006·Kidney & Blood Pressure Research·Michael DandelRoland Hetzer
Mar 29, 2005·Zeitschrift für Rheumatologie·G Riemekasten, H Schulze-Koops
Oct 29, 2011·Pulmonary Circulation·Ankit A Desai, Roberto F Machado
Apr 23, 2005·The Cochrane Database of Systematic Reviews·N S ParamothayanE H Walters
May 16, 2006·American Journal of Physiology. Lung Cellular and Molecular Physiology·Laimute Taraseviciene-StewartNorbert F Voelkel
May 2, 2019·The Cochrane Database of Systematic Reviews·Hayley BarnesTrevor Williams
Sep 22, 2016·Respirology : Official Journal of the Asian Pacific Society of Respirology·Sheila RamjugRobin Condliffe
Oct 10, 2001·Clinics in Chest Medicine·N GaliéA Branzi
Dec 1, 2021·Expert Review of Respiratory Medicine·Ralf EwertChristian F Opitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.